

Universal Biosensors Inc
ARBN 121 559 993

1 Corporate Avenue
Rowville VIC 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

29 July 2015

Universal Biosensors earns fourth milestone payment under Siemens collaboration

Universal Biosensors, Inc. (ASX: UBI) is pleased to announce that it has achieved the fourth out of six milestones payable under its Collaboration Agreement with Siemens Healthcare Diagnostics Inc. ("Siemens").

The milestone, which triggers a payment to UBI of US\$1 million, was achieved when Siemens made a premarket 510(k) submission to the US Food and Drug Administration (FDA) for regulatory clearance in the US of the Siemens Xprecia Stride™ Coagulation System for point-of-care testing. The Xprecia Stride™ Coagulation System is a PT-INR testing system that incorporates UBI's unique electrochemical sensing technology, which offers high performance and ease-of-use in a handheld format.

This submission follows the recent commercial launch by Siemens of the Xprecia Stride™ Coagulation System. It is being marketed through Siemens' extensive sales and distribution network in a growing number of markets, currently excluding the US, which requires FDA 510(k) clearance.

Universal Biosensors' CEO Paul Wright said: *"This is another important milestone for both Universal Biosensors and Siemens. We are confident that the Xprecia Stride™ Coagulation System will be well received in the US point-of-care market, which represents almost half of current worldwide demand for PT-INR testing."*

The Xprecia Stride™ Coagulation System is used to monitor the application of the anti-coagulant therapy, Warfarin. It is estimated that up to 10 million patients globally are taking Warfarin for the treatment of blood clots in the veins or certain heart conditions which increase the likelihood of a potentially life-threatening clot forming. Patients on Warfarin require frequent testing to assess the clotting tendency of their blood. The Prothrombin Time (PT-INR) test allows physicians to adjust patient doses for diet and lifestyle changes.

Under the terms of a supply agreement with Siemens, Universal Biosensors will manufacture the test strips used with the Siemens Xprecia Stride™ System at the Company's plant in Rowville, Victoria.

Ends

Enquiries:

Mr Paul Wright: 03 9213 9000

Universal Biosensors Inc
ARBN 121 559 993

1 Corporate Avenue
Rowville VIC 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to <http://www.universalbiosensors.com>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.